Send to:

Choose Destination
See comment in PubMed Commons below
Bull Cancer. 2011 Mar;98(3):277-90. doi: 10.1684/bdc.2011.1330.

[PARP inhibitors: significant progress in cancer therapy].

[Article in French]

Author information

  • 1UMR, BSC, CNRS-Université de Strasbourg, ESBS, poly(ADP-ribosyl)ation et intégrité du génome, Illkirch, France.


Poly(ADP-ribosyl)ation is a post-translational modification of proteins catalyzed by poly(ADP-ribose) polymerases (PARPs). In response to genotoxic stress, PARP-1 senses DNA breaks and through the synthesis of poly(ADP-ribose) restores genome integrity by stimulating a base excision and single-strand break repair process. These properties highlight the innovative potency of PARP inhibitors to target cancer cells in their repair capacity. They open the way to promising therapeutic strategies aimed to combine PARP inhibitors with DNA-damaging chimio- or radiotherapy and as single agents for the treatment of BRCA mutation-associated tumors. The benefits to potential risks ratio of these approaches will be discussed.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk